USE OF INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO RTK HYPERFUNCTION, ESPECIALLY CANCER

摘要

The invention relates to the use of inhibitors for the treatment and/or prevention of diseases resulting from increased receptor tyrosine kinase activity, especially cancer. Use concerns particularly the inhibition or reduction of over-expression and/or altered activity of receptor tyrosine kinases (RKTs). Such changes in the activity of receptor tyrosine kinase may be triggered particularly by a mutation of the FGFR-4, which mutation is especially a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic for a hydrophilic amino acid. The invention further relates to the use of an inhibitor directed against FGFR-4 for the treatment and/or prevention of cancer. The invention also relates to a mutated FGFR-4 causing overexpression and/or altered activity in cells. The invention finally relates to a DNA and RNA sequence of a mutated FGFR-4 molecule, a pharmaceutical composition comprising the inhibitor described above, and a diagnostic and screening method.